Predilife outlines its strategy to maximize its industrial and financial potential

Predilife, a specialist in disease risk prediction solutions, outlines its strategy to optimize its intellectual property assets through licensing and investment. The company is targeting various segments to maximize its returns, including access to data and risk models based on artificial intelligence.

In Europe, Predilife is focusing on MammoRisk, a study whose results are expected in 18 months, generating interest in potential partnerships. In the United States, the company is working towards FDA approval. Meanwhile, its multi-pathology tests for employees, distributed through health checkups, are seeking a buyer in the insurance sector due to their operating losses.

The company anticipates a cash horizon until December 2026, with financial results expected in May 2026.